Investor conference call First quarter of 2016...Slide 4 5,05 4,10 3,50 4,72 11,82 11,82 Highlights – First quarter of 2016 1 Adjusted operating profit accounts for partial divestment

Slide 1

5,05

4,10

3,50

4,72

11,82 11,82

Investor conference call

First quarter of 2016

Shanghai – part of Cities Changing Diabetes

Slide 2

5,05

4,10

3,50

4,72

11,82 11,82

Agenda

Investor conference call First quarter of 2016

Highlights and key events By Lars Rebien Sørensen, president and CEO

R&D update By Mads Krogsgaard Thomsen, CSO

Financials and outlook By Jesper Brandgaard, CFO

Sales update By Lars Rebien Sørensen, president and CEO

Questions and answers session

Slide 3

5,05

4,10

3,50

4,72

11,82 11,82

Forward-looking statements

Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company’s Annual Report 2015 and Form 20-F, which are both filed with the SEC in February 2016 in continuation of the publication of the Annual Report 2015, and presentations made, written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

• Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto

• Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures

• Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and

• Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.

Please also refer to the overview of risk factors in ‘Managing risks’ on p 42-43 of the Annual Report 2015.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise.

Important drug information

• Victoza® (liraglutide 1.2 mg & 1.8 mg) is approved for the management of type 2 diabetes only

• Saxenda® (liraglutide 3 mg) is approved in the US and EU for the treatment of obesity only


Slide 4

5,05

4,10

3,50

4,72

11,82 11,82

Highlights – First quarter of 2016

1 Adjusted operating profit accounts for partial divestment of NNIT and out-licensing of assets for inflammatory disorders, both in 2015


Research and Development • Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial • Tresiba® shows lower rate of hypoglycaemia than insulin glargine U100 in SWITCH trials in people with type 1 and 2 diabetes • Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial

Sales development • Sales increased by 9% in local currencies and 8% in Danish kroner

• USA and International Operations grew by 12% and 15% in local currencies, respectively • Victoza® increased by 15% in local currencies and continues to drive the growth of the GLP-1 market • Biopharm increased by 15% in local currencies, driven by non-recurring rebate adjustments for Norditropin® in the US

• New-generation insulin now accounts for 17% share of growth in local currencies

Financials • Adjusted operating profit1 increased by 10% in local currencies and 9% in Danish kroner • Diluted earnings per share decreased by 2% to 3.71 DKK per share, adjusted for the partial divestment of NNIT it increased

by 23% • 2016 financial outlook:

• Sales growth is still expected to be 5-9% measured in local currencies (around 3% lower as reported) • Adjusted operating profit growth is still expected to be 5-9% measured in local currencies (around 4% lower as reported)

Slide 5

5,05

4,10

3,50

4,72

11,82 11,82

Growth analysis – First quarter of 2016

USA is the main contributor to sales growth


Sales as reported – First quarter of 2016

Sales of DKK 27.2 billion (+8%)

Local currencies Growth Share of growth

USA 12% 64%

Europe 1% 3%

International Operations1 15% 23%

Region China 3% 4%

Pacific2 7% 6%

Total sales 9% 100%

International Operations

+3%

Region China +1%

Pacific +7%

USA +14%

Europe +1%

50%

18%

13%

11%

8%

Note: New regional structure as of Q1 2016 1 Excludes Oceania 2 Comprises Japan, Korea, Canada and Oceania

Slide 6

5,05

4,10

3,50

4,72

11,82 11,82

Local currencies Growth Share of growth

New-generation insulin1 136% 17%

Modern insulin 3% 15%

Human insulin (3%) (4%)

Victoza® 15% 27%

Other diabetes and obesity care2 16% 9%

Diabetes and obesity care 7% 64%

Haemophilia3 4% 4%

Norditropin® 32% 27%

Other biopharmaceuticals4 15% 5%

Biopharmaceuticals 15% 36%

Total 9% 100%

Sales growth is driven by Victoza® and new-generation insulin


Sales as reported – First quarter of 2016

Sales of DKK 27.2 billion (+8%)

Growth analysis – First quarter of 2016

1 Comprises Tresiba®, Ryzodeg® and Xultophy®

2 Primarily NovoNorm®, needles and Saxenda®

3 Comprises NovoSeven®, NovoEight® and NovoThirteen®

4 Primarily Vagifem® and Activelle®

Other +15%

7% Haemophilia +4%

11%

Diabetes and obesity care

+6%

79%

3%

77%

10%

9% 4%

Norditropin®

+32%

Note: Norditropin® Q1 sales growth is derived primarily from USA reflecting a positive non-recurring adjustment to rebates in the Medicaid patient segment

Slide 7

5,05

4,10

3,50

4,72

11,82 11,82

Source: IMS NPA MAT, March 2016

US GLP-1 market development

Source: IMS NPA MAT, March 2016


Total TRx Growth rate

US GLP-1 market shares

exenatide Victoza®

albiglutide dulaglutide MAT GLP-1 TRx (000)

GLP-1 TRx market share

MAT volume growth rate

Victoza® maintains leadership in the faster growing US GLP-1 market

Mar 2016

Mar 2013

54%

9%

16%

21%

0%

20%

40%

60%

80%

100%

0%

5%

10%

15%

20%

25%

30%

35%

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

Thousands

Mar 2013

Mar 2016

Slide 8

5,05

4,10

3,50

4,72

11,82 11,82

34%

7%

13%

8% 6%

4%

13%

16% 15%

28%

3%

0%

5%

10%

15%

20%

25%

30%

35%

0 4 8 12 16 20 24 28 32 36

• Tresiba® launched in 43 countries with solid penetration in markets with similar reimbursement as insulin glargine

• Ryzodeg® commercially launched in Mexico, India,

Bangladesh, Japan and now Russia

• Xultophy® launched in Switzerland, Germany, the United Kingdom, Sweden and now Hungary

Key launch observations Tresiba® value share of basal insulin segment

in selected countries, excl US

Roll-out of new-generation insulin portfolio is progressing

Note: Limited IMS coverage in India Source: IMS Monthly value figures, February 2016


Months from launch

Mexico

Switzerland Japan Sweden

Denmark

Netherlands Argentina Brazil

UK India Greece Italy

27% 25%

Spain

36

Slide 9

5,05

4,10

3,50

4,72

11,82 11,82

Weekly US NBRx volume market shares

Encouraging uptake of Tresiba® in the US

Source: IMS weekly data, 1 April 2016, excludes Medicaid


Tresiba® launched in the US

• Full commercial launch in January 2016 following specialist engagement in Q4 2015

• Total Novo Nordisk new-to-brand prescription volume market share has increased by 3.4% in 2016 in the basal segment

• Tresiba® monthly volume market share has reached 1.4%

• Tresiba® U200 accounts for around two-thirds of Tresiba® prescriptions

• Wide formulary access has been obtained in both Part D and commercial channels

0%

10%

20%

30%

40%

50%

01/01/2016

Levemir® NN Total Basal Tresiba®

glargine U100 glargine U300

Jan 2016

Apr 2016

45%

31%

22%

16%

8%

Note: The graph does not show NPH, which accounts for the residual market share Source: IMS weekly data, 1 April 2016, excludes Medicaid NBRx: New-to-brand prescription counts; MS: Market share

Basal NBRx MS

Slide 10

5,05

4,10

3,50

4,72

11,82 11,82

LEADER trial design Headline results

Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial

T2DM: Type 2 diabetes mellitus


Standard of care + placebo (daily blinded injection)

Standard of care + liraglutide (0.6-1.8 mg once daily)

0 3.5-5.0 years

9,340 patients with T2DM

Key inclusion criteria

• Adults above 50 years with T2DM and established cardiovascular disease, or above 60 years with multiple cardiovascular risk factors

• HbA1c 7.0%

• Non-inferiority as well as superiority demonstrated for primary end-point of major cardiovascular events (MACE), with a statistically significant reduction

• Superior reduction in cardiovascular risk was derived from all three components of the end-point (CV death, MI, stroke)

• Safety and tolerability profile of liraglutide in LEADER was generally consistent with previous liraglutide studies

• 13 June 2016: Presentation of LEADER results at the American Diabetes Association 2016 conference

• H2 2016: Submission of LEADER data to regulatory authorities as part of post-approval commitments

Key milestones

MI: Myocardial infarct

Slide 11

5,05

4,10

3,50

4,72

11,82 11,82

Tresiba® shows lower rate of hypoglycaemia than insulin glargine U100 in SWITCH trials – filing expected Q3 2016


2,463

429 92

2,201

277 69 0

500

1,000

1,500

2,000

2,500

3,000

Severe or BG

confirmed

symptomatic

events

Severe or BG

confirmed

symptomatic

nocturnal events

Severe events

SWITCH 1 – type 1 diabetes SWITCH 2 – type 2 diabetes

Note: The prevalence of hypoglycaemia is measured during the maintenance period; Blood glucose confirmed hypoglycaemia is defined as <56 mg/dL (<3.1 mmol/L); The confirmatory secondary endpoint of proportions of subjects experiencing severe hypoglycaemia during the maintenance period did not reach statistical significance in the SWITCH 2 trial. * Statistically significant; BG: Blood glucose; PYE: Patient years exposed

265

94

9

186

55 5 0

50

100

150

200

250

300

Severe or BG

confirmed

symptomatic

events

Severe or BG

confirmed

symptomatic

nocturnal events

Severe events

-11%*

-36%*

-35%*

-30%*

-42%*

-46%

Tresiba® glargine U100 Hypoglycaemic events per 100 PYE

Hypoglycaemic events per 100 PYE

Slide 12

5,05

4,10

3,50

4,72

11,82 11,82

• Non-inferiority demonstrated for the primary endpoint of major cardiovascular events (MACE) with semaglutide compared with placebo, with a statistically significant reduction of MACE

• The trial accrued around 250 MACE

• The primary endpoint of the study was defined as the composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke

• Safety profile of semaglutide in SUSTAIN 6 was as expected and consistent with previous semaglutide clinical studies

1 Inclusion criteria: Age ≥ 50 years with clinical evidence of CV disease or ≥ 60 years with subclinical evidence of CV disease, HbA1c ≥ 7.0 %, standard-of-care treatment 0-2 OAD, basal or pre-mix insulin with/without 0-2 OAD OAD: Oral anti-diabetic

SUSTAIN 6 trial design

Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial


Headline results

~3,300 patients with type 2 diabetes1

Week 0 Treatment duration 104

Semaglutide 0.5 mg QW

Semaglutide 1.0 mg QW

Placebo 0.5 mg QW

Placebo 1.0 mg QW

Slide 13

5,05

4,10

3,50

4,72

11,82 11,82

Key development milestones


SUSTAIN 5 comparing semaglutide with insulin glargine U100 successfully completed

Phase 3a trial, PIONEER 3, initiated comparing oral semaglutide (NN9924) with sitagliptin

Advisory Committee meeting scheduled on 24 May 2016 with the FDA to discuss IDegLira (NN9068)

Positive results from phase 3a trial with long-acting growth hormone, somapacitan (NN8640), for treatment of Adult Growth Hormone Deficiency (AGHD)

Slide 14

5,05

4,10

3,50

4,72

11,82 11,82

Strong R&D newsflow expected to continue in 2016


Project Past 6 months Past 3 months Within 3 months In ~3-6 months

Tresiba® SWITCH 2

Victoza®

Amylin analogue

Results available

In ~6-9 months

Xultophy®

SUSTAIN 6

LEADER

Phase 1

FDA regulatory decision

Phase 1

Once-weekly semaglutide

SWITCH 1 DEVOTE √

Glucagon 530L

SUSTAIN 2 √

SUSTAIN 4 √

Note: Indicated timeline as of financial release of first quarter of 2016 on 29 April 2016; 1 Study conducted in adult growth hormone disorder

SUSTAIN 5

OI338GT Phase 2a

N9-GP US submission

Diabetes Obesity Haemophilia

Somapacitan Phase 3a1

Growth disorders

√

√

√

√

√

Variation application in the US

Regulatory milestone

Variation application in the US and EU

Faster-acting US submission

FDA AdComm

US and EU submission

Slide 15

5,05

4,10

3,50

4,72

11,82 11,82

DKK million Q1 2016 Q1 2015 Change Sales 27,212 25,200 8% Gross profit 22,978 21,326 8% Gross margin 84.4% 84.6%

Sales and distribution costs 6,741 6,147 10% Percentage of sales 24.8% 24.4%

Research and development costs 3,304 3,250 2% Percentage of sales 12.1% 12.9%

Administration costs 908 854 6% Percentage of sales 3.3% 3.4%

Other operating income, net 284 2,782 N/A Non-recurring income from the IPO of NNIT - 2,376

Operating profit 12,309 13,857 (11%)1

Financial items (net) (356) (1,372) N/A

Profit before income tax 11,953 12,485 (4%) Tax 2,498 2,609 (4%) Effective tax rate 20.9% 20.9%

Net profit 9,455 9,876 (4%) Diluted earnings per share (DKK) 3.71 3.79 (2%) Diluted earnings per share (DKK) adjusted for partial divestment of NNIT 3.71 3.02 23%

Financial results – First quarter of 2016

1 Adjusted operating profit, accounting for the partial divestment of NNIT and out-licensing of inflammation assets, increased by 10% in local currencies


Slide 16

5,05

4,10

3,50

4,72

11,82 11,82

40

60

80

100

120

140

80

85

90

95

100

105

110

115

120

125

Depreciation of key currencies against the Danish krone drives negative currency impact in 2016


Hedged c

urr

encie

s

Index (

1 J

an 2

015=

100)

CNY/DKK JPY/DKK USD/DKK

Non-h

edged c

urr

encie

s

Index (

1 J

an 2

015 =

100)

CAD/DKK GBP/DKK

1 DKK per 100; 2 As of 26 April 2016; 3 Operating profit in DKK million per annum; 4 USD and Chinese Yuan traded offshore (CNH) used as proxy

Note: Operating profit impact of one of the non-hedged currencies fluctuating 5% is in the range of DKK -15 to +30 million

Hedged Currencies

2015 average

2016 average2

Spot rate2

Impact of a 5% move3

Hedging (months)

USD1 673 673 659 2,000 12

CNY1 107.0 103.0 101.5 300 114

JPY1 5.56 5.90 5.93 160 11

GBP1 1,028 962 960 85 12

CAD1 526 496 521 70 11

Non-hedged Currencies

2015 average

2016 average2

Spot rate2

RUB1 11.06 9.23 9.94

INR1 10.49 9.99 9.90

ARS1 0.73 0.47 0.46

BRL1 205 176 186

TRY1 248 230 233

INR/DKK ARS/DKK RUB/DKK TRY/DKK BRL/DKK

2015

3 1 2 4 1

2016

Slide 17

5,05

4,10

3,50

4,72

11,82 11,82

Financial outlook for 2016

The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 26 April 2016


Sales growth - local currencies

Sales growth - reported

Operating profit growth - local currencies

Operating profit growth - reported

Financial items (net)

Effective tax rate

Capital expenditure

Free cash flow

Depreciation, amortisation and impairment losses

Expectations 29 Apr 2016

5-9%

Around 3 percentage points lower

5-9%

Loss of around DKK 200 million

20-22%

Around DKK 7.0 billion


Around DKK 35-38 billion

Previous expectations 3 Feb 2016

5-9%

Around 1 percentage point lower

5-9%

Around 1 percentage point lower

Loss of around DKK 1.3 billion

20-22%



Around DKK 36-39 billion

Around 4 percentage points lower

Slide 18

5,05

4,10

3,50

4,72

11,82 11,82

Source: IMS MAT February 2016 volume and value (DKK) figures

Solid market performance Promising pipeline

Closing remarks


> > • The only company with a full portfolio of novel insulin products

• Semaglutide portfolio offers expansion opportunity with both injectable and oral administration

• Xultophy® supports promising outlook for insulin and GLP-1 combination therapy

• Saxenda® and multiple early stage development projects hold potential within obesity

• Broad pipeline within haemophilia and growth hormone disorders

• ≥10% annual diabetes care market growth driven by diabetes prevalence

• 27% market share in diabetes care and solid leadership position

• 46% insulin volume market share with leadership position across all regions

• 45% modern and new-generation insulin volume market share

• 64% GLP-1 value market share with strong global leadership position

Slide 19

5,05

4,10

3,50

4,72

11,82 11,82

Share information Investor Relations contacts

Investor contact information


Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For further company information, visit Novo Nordisk on the internet at: novonordisk.com

Peter Hugreffe Ankersen +45 3075 9085 [email protected]

Daniel Bohsen +45 3079 6376 [email protected]

Melanie Raouzeos +45 3075 3479 [email protected]

In North America:

Kasper Veje +1 609 235 8567 [email protected]

Novo Nordisk A/S Investor Relations Novo Allé, DK-2880 Bagsværd

Upcoming events

18 May 2016 Thematic call on Sustainability

13 Jun 2016 Investor and analyst event in connection with ADA

05 Aug 2016 Financial statement for the first six months of 2016

28 Oct 2016 Financial statement for the first nine months of 2016

02 Feb 2017 Financial statement for 2016

mailto:[email protected]




Documents

Investor conference call First quarter of 2016...Slide 4 5,05 4,10 3,50 4,72 11,82 11,82 Highlights – First quarter of 2016 1 Adjusted operating profit accounts for partial divestment